249 related articles for article (PubMed ID: 19808198)
1. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.
Tyagi P; Mirakhur B
Clin Lung Cancer; 2009 Sep; 10(5):371-4. PubMed ID: 19808198
[TBL] [Abstract][Full Text] [Related]
2. MAGE A3 antigen-specific cancer immunotherapeutic.
Peled N; Oton AB; Hirsch FR; Bunn P
Immunotherapy; 2009 Jan; 1(1):19-25. PubMed ID: 20635969
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
[TBL] [Abstract][Full Text] [Related]
5. [Molecular biology of lung cancer series].
Hiret S; Senellart H; Bennouna J
Rev Mal Respir; 2010 Oct; 27(8):954-8. PubMed ID: 20965409
[TBL] [Abstract][Full Text] [Related]
6. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
7. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
[TBL] [Abstract][Full Text] [Related]
8. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
[TBL] [Abstract][Full Text] [Related]
9. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer.
Shigematsu Y; Hanagiri T; Shiota H; Kuroda K; Baba T; Mizukami M; So T; Ichiki Y; Yasuda M; So T; Takenoyama M; Yasumoto K
Lung Cancer; 2010 Apr; 68(1):105-10. PubMed ID: 19545928
[TBL] [Abstract][Full Text] [Related]
11. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance.
Yoshida N; Abe H; Ohkuri T; Wakita D; Sato M; Noguchi D; Miyamoto M; Morikawa T; Kondo S; Ikeda H; Nishimura T
Int J Oncol; 2006 May; 28(5):1089-98. PubMed ID: 16596224
[TBL] [Abstract][Full Text] [Related]
12. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
Perez CA; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
[TBL] [Abstract][Full Text] [Related]
13. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.
Bolli M; Kocher T; Adamina M; Guller U; Dalquen P; Haas P; Mirlacher M; Gambazzi F; Harder F; Heberer M; Sauter G; Spagnoli GC
Ann Surg; 2002 Dec; 236(6):785-93; discussion 793. PubMed ID: 12454517
[TBL] [Abstract][Full Text] [Related]
14. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
Grah J; Samija M; Juretić A; Sarcević B; Sobat H
Coll Antropol; 2008 Sep; 32(3):731-6. PubMed ID: 18982744
[TBL] [Abstract][Full Text] [Related]
15. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
Reck M
Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
[TBL] [Abstract][Full Text] [Related]
16. Expression of melanoma-antigen-A (MAGE-A) in disseminated tumor cells in regional lymph nodes of patients with operable non-small cell lung cancer.
Dango S; Wang XT; Gold M; Cucuruz B; Klein CA; Passlick B; Sienel W
Lung Cancer; 2010 Mar; 67(3):290-5. PubMed ID: 19467731
[TBL] [Abstract][Full Text] [Related]
17. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
18. Expression of MAGE-D4, a novel MAGE family antigen, is correlated with tumor-cell proliferation of non-small cell lung cancer.
Ito S; Kawano Y; Katakura H; Takenaka K; Adachi M; Sasaki M; Shimizu K; Ikenaka K; Wada H; Tanaka F
Lung Cancer; 2006 Jan; 51(1):79-88. PubMed ID: 16225959
[TBL] [Abstract][Full Text] [Related]
19. Is vaccine therapy a renewed strategic approach for non-small-cell lung cancer therapy?
Rossi A
Expert Rev Vaccines; 2013 Jan; 12(1):5-7. PubMed ID: 23256734
[No Abstract] [Full Text] [Related]
20. First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen.
Takahashi N; Ohkuri T; Homma S; Ohtake J; Wakita D; Togashi Y; Kitamura H; Todo S; Nishimura T
Cancer Sci; 2012 Jan; 103(1):150-3. PubMed ID: 22221328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
